ARGENX SE
Last · NasdaqGS$818.30+15.66 (+1.95%)close · yahoo · 19h ago
Market cap$51.46B62.9M sh
P/E · TTM31.2fwd 23.0 · eps 26.24
Beta-0.04vs S&P 500
Div yield0.00%annual · TTM
52w range
$661.85$1072.75
Volume462.4Ksession
| Revenue | $35.5M |
|---|---|
| Operating income | $-425.0M |
| Net income | $-295.1M |
| Free cash flow | $-421.1M |
| Operating margin | -1196.2% |
| Net margin | -830.4% |
| Return on equity | -7.2% |
| Period | 2023 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 20-F · 2025-03-20
- Operating Cf Burn
Red flags
- Operating Cf Burn — Negative operating cash flow
Upcoming earnings
2:30 PM UTC+2
Period
Sep 2026
Est. EPS
−$9.77
Est. revenue
1.6B
Press & signals
- GlobeNewswire
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- GlobeNewswire
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- GlobeNewswire
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans